Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

Michel Attal, Jean‐François Rossi, Philippe Casassus et al. · New England Journal of Medicine · 1996 · 2.6K citations · Full text

Medicine, Hematology, Oncology +14

Improved survival in multiple myeloma and the impact of novel therapies

Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood · 2007 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA

M Ichel A Ttal, J Ean, A.A. D uuml nne et al. · 2013 · 2.2K citations

Medicine, Hematology, Oncology +14

High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

J. A. Child, Gareth J. Morgan, Faith E. Davies et al. · New England Journal of Medicine · 2003 · 1.8K citations · Full text

Medicine, Hematology, Oncology +17

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

S. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander et al. · The Lancet Oncology · 2009 · 933 citations · Full text

Medicine, Hematology, Oncology +11